Related Experiment Video
Updated: May 29, 2026
07:51
Development and Functionalization of Electrolyte-Gated Graphene Field-Effect Transistor for Biomarker Detection
Published on: February 1, 2022
Insulin-binding aptamer-conjugated graphene oxide for insulin detection
1Xiangya Hospital, Central South University, P.O. Box 190. Changsha, Hunan 410008, China.
The Analyst
|August 30, 2011
Summary
This study presents a novel aptamer/graphene oxide assay for sensitive insulin detection. The method uses target-induced aptamer release and enzymatic cleavage for signal amplification, achieving a low limit of detection.
Area of Science:
- Biomedical Engineering
- Analytical Chemistry
- Nanotechnology
Background:
- Graphene oxide (GO) offers protective properties for DNA against nuclease degradation.
- Aptamers are crucial recognition elements in biosensing applications.
- Insulin detection is vital for diabetes management and monitoring.
Purpose of the Study:
- To develop a simple and highly sensitive assay for insulin detection.
- To leverage the properties of graphene oxide and aptamers for enhanced biosensing.
- To achieve significant signal amplification for low-limit detection.
Main Methods:
- Utilized an aptamer/graphene oxide (GO) platform for insulin detection.
- Exploited GO's ability to protect DNA from nuclease cleavage.
- Implemented target-induced aptamer detachment from the GO surface.
- Incorporated enzymatic cleavage of released aptamers for signal amplification.
- Enabled target recycling for enhanced sensitivity.
Main Results:
- Demonstrated a sensitive assay for insulin detection.
- Achieved significant signal amplification through a cyclic process.
- Reported a low limit of detection (LOD) for insulin.
Conclusions:
- The aptamer/GO based assay is a promising tool for sensitive insulin detection.
- The proposed method offers a simple and effective approach for biosensing.
- The signal amplification strategy is effective for achieving low LOD.
Related Concept Videos
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:25Insulin: Biosynthesis, Chemistry, and Preparation
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...